Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best Middle East and Africa stocks to buy according to hedge funds.
On April 29, Teva Pharmaceutical Industries Limited (NYSE:TEVA) reported its Q1 FY2026 earnings, where it revealed that revenue was $4.0 billion for the quarter
This is a 2% year over year increase and a beat against analyst estimates of about $3.79 billion. Non-GAAP diluted EPS was $0.53, a 10% beat against the consensus estimate. Management hosted an earnings call on the same day and took the time to explain that the revenue beat was powered by the company’s innovative portfolio growing 41% collectively.
They added that the EPS beat was tied directly to a better-than-expected gross margin of 52.9%, and that this reflects the growing mix of high-margin innovative products within overall revenue. CFO Eli Kalif noted during the earnings call that the gross margin outperformed internal expectations due to a favorable product mix within generics as well. The flip side was that non-GAAP operating margin dipped about 50 basis points year on year to 24%, Kalif noted.